BioSpace News Archive

Gilead Sciences, Inc. announced new data from the Phase 3 ASCENT study evaluating Trodelvy® in patients with relapsed or refractory metastatic triple-negative breast cancer who received two or more prior systemic therapies, at least one of them for metastatic disease.

Newron Pharmaceuticals S.p.A., a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, announced its operational highlights and financial results for the half-year ended June 30, 2021.

VectivBio Holding AG, a clinical-stage biopharmaceutical company pioneering novel transformational treatments for severe rare conditions, announced upcoming investor events.

Bantam Pharmaceutical today announced that it has completed a $25 million Seed Funding to finalize its ongoing IND-enabling activities for its lead program, BTM-3566, and consummate preparations for first in human clinical trials.

First-of-its-kind study will evaluate safety and efficacy of CNP-201, a nanoparticle containing peanut protein, in eliminating allergic responses

Sonoma Biotherapeutics today announced the appointment of Doug Sheehy, J.D., as Chief Legal Officer and Secretary.

Caraway Therapeutics today announced that the Company’s Chief Executive Officer, Martin D. Williams, will present at the virtual Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on Thursday, September 23, 2021 at 2:55pm Eastern Time.

Company obtains exclusive rights to potential best-in-class ULK1/2 inhibitor for LKB1 and RAS-mutated cancers where there is a significant unmet need

ARCA biopharma, Inc. today announced that the first international patient has been enrolled in ASPEN-COVID-19, the Phase 2b clinical trial evaluating rNAPc2 as a potential treatment for patients hospitalized with COVID-19.

Prodeon Medical, Inc., a medical device company developing a novel, minimally invasive treatment for lower urinary tract symptoms (LUTS) caused by enlarged and obstructive benign prostatic hyperplasia (BPH), today announced the availability of interim results of its EXPANDER-1 clinical study using the Urocross Expander System (previously branded as the XFLO).